Cargando…

Predictive Value of Clinical Judgment of Tumour Progression in Phase II Trials

BACKGROUND: The diagnosis of tumour progression or progressive disease (PD) is a key element for designing and interpreting contemporary phase II trials. In some cases, PD is stated by the physician and is not formally confirmed by imaging. PURPOSE: In this study, we intend to analyze the value of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotecki, Nuria, Penel, Nicolas, Adenis, Antoine, Ferte, Charles, Clisant, Stéphanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3530434/ https://www.ncbi.nlm.nih.gov/pubmed/23300731 http://dx.doi.org/10.1371/journal.pone.0052638

Ejemplares similares

Frequency of Certain Established Risk Factors in Soft Tissue Sarcomas in Adults: A Prospective Descriptive Study of 658 Cases
por: Penel, Nicolas, et al.
Publicado: (2008)

Dose-Levels and First Signs of Efficacy in Contemporary Oncology Phase 1 Clinical Trials
por: Ferte, Charles, et al.
Publicado: (2011)

Once weekly paclitaxel associated with a fixed dose of oral metronomic cyclophosphamide: a dose-finding phase 1 trial
por: Pannier, Diane, et al.
Publicado: (2018)

Development and Validation of a Bedside Score to Predict Early Death in Cancer of Unknown Primary Patients
por: Penel, Nicolas, et al.
Publicado: (2009)

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial
por: Brodowicz, Thomas, et al.
Publicado: (2015)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)
por: Lebellec, Loic, et al.
Publicado: (2016)

High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas
por: Groothuis, Patrick, et al.
Publicado: (2021)

Impact of early palliative care on overall survival of patients with metastatic upper gastrointestinal cancers treated with first-line chemotherapy: a randomised phase III trial
por: Hutt, Emilie, et al.
Publicado: (2018)

Life-Threatening Irinotecan-Induced Toxicity in an Adult Patient with Alveolar Rhabdomyosarcoma: The Role of a UGT1A1 Polymorphism
por: Jannin, Arnaud, et al.
Publicado: (2017)

PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model)
por: Grellety, Thomas, et al.
Publicado: (2016)

Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard care
por: Penel, N, et al.
Publicado: (2010)

Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO)(†)
por: Bompas, E., et al.
Publicado: (2015)

Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based study
por: Ligier, Karine, et al.
Publicado: (2015)

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial
por: Messager, Mathieu, et al.
Publicado: (2016)

Judgment in Cardiology—Part II
por: Turner, Richard W. D.
Publicado: (1949)

Clinical complete responders to definite chemoradiation or radiation therapy for oesophageal cancer: predictors of outcome
por: Adenis, Antoine, et al.
Publicado: (2013)

On value judgments in the arts and other essays
por: Olson, Elder 1909-
Publicado: (1976)

Contributing factors in judgment of fairness by monetary value
por: Tam, David Nicoladie
Publicado: (2011)

Science and Policy: Understanding the Role of Value Judgments
por: Pelley, Janet L.
Publicado: (2014)

Commentary: Value Judgments in Health Inequality Measurement
por: Wagstaff, Adam
Publicado: (2015)

Ethics and Social Value Judgments in Public Health
por: Ng, N.Y., et al.
Publicado: (2014)

Moral foundations, values, and judgments in extraordinary altruists
por: Amormino, Paige, et al.
Publicado: (2022)

FOLFIRINOX-R study design: a phase I/II trial of FOLFIRINOX plus regorafenib as first line therapy in patients with unresectable RAS-mutated metastatic colorectal cancer
por: Adenis, Antoine, et al.
Publicado: (2021)

REGOSARC: Regorafenib versus placebo in doxorubicin‐refractory soft‐tissue sarcoma—A quality‐adjusted time without symptoms of progression or toxicity analysis
por: Berry, Vincent, et al.
Publicado: (2017)

Judgments at Gaze Value: Gaze Cuing in Banner Advertisements, Its Effect on Attention Allocation and Product Judgments
por: Palcu, Johanna, et al.
Publicado: (2017)

Attention and cardiac phase boost judgments of trust
por: Li, Xinyi, et al.
Publicado: (2020)

Predeliberation activity in prefrontal cortex and striatum and the prediction of subsequent value judgment
por: Maoz, Uri, et al.
Publicado: (2013)

The Role of Predictability During Negation Processing in Truth-Value Judgment Tasks
por: Rück, Franziska, et al.
Publicado: (2021)

Phase II trial of raltitrexed ('Tomudex') in advanced small-cell lung cancer.
por: Woll, P. J., et al.
Publicado: (1997)

Health care: the challenge to deal with uncertainty and value judgment
por: Ferraz, Marcos Bosi
Publicado: (2015)

Explanatory Judgment, Moral Offense and Value-Free Science
por: Colombo, Matteo, et al.
Publicado: (2015)

P-values, survival analyses and phase II trials.
por: Fayers, P.
Publicado: (1994)

Visiting Richard Serra’s “Promenade” sculpture improves postural control and judgment of subjective visual vertical
por: Kapoula, Zoï, et al.
Publicado: (2014)

Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
por: Jones, Robin L., et al.
Publicado: (2019)

Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial
por: Samalin, E, et al.
Publicado: (2014)

Judgment
por: Blackmarr, C. B.
Publicado: (1897)

Nomogram to Predict Treatment Outcome of Fluoropyrimidine/Platinum-Based Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma
por: Jung, Hyun Ae, et al.
Publicado: (2013)

Improving clinical judgment by simulation: a randomized trial and validation of the Lasater clinical judgment rubric in Chinese
por: Yang, Fen, et al.
Publicado: (2019)

The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers
por: Mariette, Christophe, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_66is0vqvcfm4khtkt3a1kt5kl5